Cervical Cancer
Conditions
Brief summary
The study is being conducted to evaluate the efficacy, and safety of SHR-1701 or Placebo Plus Chemotherapy With or Without BP102 (Bevacizumab) as First-Line Treatment in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer.
Interventions
DRUGSHR-1701 + paclitaxel + cisplatin/carboplatin + BP102
SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102
DRUGSHR-1701 + paclitaxel + cisplatin/carboplatin± BP102
SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102
DRUGPlacebo + paclitaxel + cisplatin/carboplatin ± BP102
Placebo + paclitaxel + cisplatin/carboplatin ± BP102
Sponsors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
SHR-1701 or Placebo Plus Chemotherapy With or Without BP102 (Bevacizumab)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Aged 18-70 years, female. 2. With Eastern Cooperative Oncology Group (ECOG) performance status scores of 0-1. 3. With a life expectancy of ≥ 12 weeks. 4. Acute toxicities from prior anti-tumor treatments must have resolved to Grade 0-1 (per NCI CTCAE 5.0). 5. With at least one measurable lesion as per RECIST v1.1. 6. With histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the cervix. 7. Persistent, recurrent, or metastatic cervical cancer. 8. Patients to be enrolled in Stage II are required to provide a minimum of 10 slides of fresh (preferred). 9. Women of childbearing potential must have a negative serum pregnancy test within 3 days prior to starting study treatment. 10. Patients must agree and have signed the informed consent form.
Exclusion criteria
1. With known contraindications to paclitaxel, cisplatin, or carboplatin. 2. With known allergies to any of the study drugs or their excipients; severe allergic reactions to other monoclonal antibodies. 3. With inadequately treated CNS metastasis. 4. With uncontrolled hypertension. 5. With uncontrolled cardiac diseases or symptoms. 6. With major vascular disease. 7. With arterial/venous thrombotic events within 6 months prior to randomization. 8. Have received full-dose anticoagulant or hemolytic therapy within 10 days prior to randomization. 9. With clinically significant hemorrhage or definitive bleeding diathesis within 3 months prior to randomization. 10. With severe, unhealed, or open wounds as well as active ulcers or untreated fractures. 11. With any active autoimmune disease or a history of autoimmune disease that is expected to recur. 12. Had other active malignant tumors within 5 years prior to study enrolment. 13. With congenital or acquired immunodeficiency (such as HIV-infected patients).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and severity of Participants Who Experience an Adverse Event (AE) as per NCI-CTC AE 5.0（Stage I） | Up to approximately 21 days |
| Incidence and severity of Participants Who Experience a Serious AE (SAE) as per NCI-CTC AE 5.0（Stage I） | Up to approximately 21 days |
| Incidence and severity of Participants Who Experience an Immune-related AE (irAE) as per NCI-CTC AE 5.0（Stage I） | Up to approximately 21 days |
| BIRC-assessed progression-free survival (PFS) as per RECIST v1.1（Stage II） | Up to approximately 10 months |
| OS is defined as the time from randomization to death due to any cause. （Stage II） | Up to approximately 26 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) up to approximately 26 months（Stage I） | up to approximately 26 months | — |
| Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by BIRC- and investigator（Stage II） | Up to approximately 26 months | — |
| Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BIRC- and investigator（Stage II） | Up to approximately 26 months | — |
| Disease Control Rate (DCR)Per RECIST 1.1 as Assessed by BIRC- and investigator（Stage II） | Up to approximately 26 months | — |
| Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by Investigator （Stage I） | Up to approximately 26 months | — |
| Time to Progress(TTP) up to approximately 26 months （Stage II） | up to approximately 26 months | The time from the date of randomization to the date of the first recording of tumor progression (as measured according to THE RECIST v1.1 criteria, regardless of whether treatment is continued or not). |
| Incidence and severity of Participants Who Experience an Adverse Event (AE) as per NCI-CTC AE 5.0 （Stage II） | Up to approximately 26 months | — |
| Incidence and severity of Participants Who Experience a Serious AE (SAE) as per NCI-CTC AE 5.0（Stage II） | Up to approximately 26 months | — |
| Incidence and severity of Participants Who Experience an Immune-related AE (irAE) as per NCI-CTC AE 5.0（Stage II） | Up to approximately 26 months. | — |
| Duration of Response (DOR) Per RECIST 1.1 as Assessed by BIRC- and investigator （Stage II） | Up to approximately 26 months | — |
| Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Investigator （Stage I） | Up to approximately 26 months | — |
| Disease Control Rate (DCR)up to approximately 26 months（Stage I） | up to approximately 26 months | — |
| Duration of Response (DOR) Per RECIST 1.1 as Assessed by Investigator （Stage I） | Up to approximately 26 months | — |
| Time to Progress(TTP) up to approximately 26 months（Stage I） | up to approximately 26 months | The time from the date of the first medication to the date of the first recording of tumor progression (as measured according to THE RECIST v1.1 criteria, regardless of whether treatment is continued or not). |
Countries
China
Outcome results
None listed